

INVESTOR WEBINAR PRESENTATION

Nova Eye Medical Limited (ASX: EYE)(**Nova Eye Medical** or the **Company**), a medical technology company committed to advanced ophthalmic treatment technologies and devices, is pleased to announce its participation in the ShareCafe Small Cap "Hidden Gems" Webinar, to be held Friday 15th of September 2023 from 12:30pm AEST/ 10:30am AWST.

Tom Spurling, Managing Director, will provide an overview of the Company, including the recent release of a new glaucoma surgical device, iTrack™ Advance into the USA market. This represents a large fast-growing market. The Company recently announced strong sales growth of 32% for the period following introduction of iTrack™ Advance.

The webinar can be viewed live via Zoom. To access further details of the event and to register, please copy and paste the following link into your internet browser:

https://us02web.zoom.us/webinar/register/WN_zrq9ssuQYSfHJiZParTCw

A recorded copy of the webinar will be made available following the event.

This release dated 15 September 2023 has been authorised for lodgement to ASX by the Board of Directors of Nova Eye Medical Limited and lodged by Simon Gray, Company Secretary.

– ENDS –

Company	Company	Investors
Tom Spurling	Kate Hunt	Mark Flynn
Managing Director	Chief Commercial Officer	Investor Relations
+61 417 818 658	+61 404 080 679	+61 416 068 733
tspurling@nova-eye.com	khunt@nova-eye.com	mflynn@nova-eye.com

ABOUT ALPHARET PTY LTD

AlphaRET Pty Ltd (AlphaRET) is a wholly owned subsidiary of Nova Eye Medical Limited. AlphaRET is focussed on executing the commercialization efforts for 2RT®

For additional information about AlphaRET and 2RT®, please visit: www.alpha-RET.com

ABOUT NOVA EYE MEDICAL

Nova Eye Medical Limited is a medical technology company that develops, manufactures and sells a portfolio of proprietary ophthalmic treatment technologies and devices. Used by eye surgeons in more than 100 countries globally, these technologies include iTrack™ minimally invasive glaucoma surgery (MIGS), a consumable surgical device that restores the eye's natural outflow pathway to lower pressure inside the eye and to eliminate patient reliance on anti-glaucoma medications for mild-moderate glaucoma. The Molteno3® glaucoma drainage device platform is designed to enhance surgical utility and optimize clinical outcomes for long-term IOP control in cases of severe glaucoma. It also offers the benefit of a simplified and faster surgical procedure. With its sales headquarters based in Fremont, California, Nova Eye Medical is supported by a global network of more than 50 distribution partners. Manufacturing facilities are located in Fremont, California and Dunedin, New Zealand.

For additional information about Nova Eye Medical and its technologies, please visit: www.nova-eye.com